Literature DB >> 10390290

Pituitary gland gumma in congenital syphilis after failed maternal treatment: a case report.

A E Benzick1, D P Wirthwein, A Weinberg, G D Wendel, R Alsaadi, N K Leos, F Zeray, P J Sánchez.   

Abstract

A preterm, very low birth weight infant was born to a mother with early latent syphilis who was treated 10 days and 3 days before delivery with 2.4 mU of benzathine penicillin. The infant had clinical, laboratory, and radiographic abnormalities consistent with congenital syphilis, ie, a Venereal Disease Research Laboratory test titer that was fourfold greater than was the maternal titer, hepatosplenomegaly, abnormal liver function tests, pneumonitis, osteochondritis of the long bones, and cerebrospinal fluid (CSF) examination showing a reactive Venereal Disease Research Laboratory test, pleocytosis, and elevated protein content. The infant died on the third day of life, and an autopsy revealed an evolving gumma of the anterior pituitary. Immunoglobulin M immunoblotting of serum and CSF was positive, and polymerase chain reaction detected Treponema pallidum DNA in endotracheal aspirate and CSF. This case highlights the pathologic abnormalities observed in congenital syphilis and focuses on the rare finding of an evolving anterior pituitary gumma. Furthermore, it documents the failure of maternal syphilis treatment during the last 4 weeks of pregnancy to cure fetal infection and supports the recommendation that all infants born to mothers with syphilis treated during the last 4 weeks of pregnancy should receive penicillin therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390290     DOI: 10.1542/peds.104.1.e4

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  1 in total

1.  Acute hypophysitis and hypopituitarism in early syphilitic meningitis in a HIV-infected patient: a case report.

Authors:  Christoph D Spinner; Sebastian Noe; Christiane Schwerdtfeger; Antonia Todorova; Jochen Gaa; Roland M Schmid; Dirk H Busch; Michael Neuenhahn
Journal:  BMC Infect Dis       Date:  2013-10-17       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.